A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
This study evaluated a difficult-to-treat Crohn's disease patient population
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
Subscribe To Our Newsletter & Stay Updated
